Lebrikizumab

ๆฅ็‘žๅฅ‡็ ๅ•ๆŠ—

Report date: 2026/04/22 20:01:10

Base Information

Drug NameLebrikizumab
Drug Alias Nameๆฅ้‡‘็ ๅ•ๆŠ—Anti-interleukin-13-monoclonal-antibodyAnti-IL 13ไน็‘žๅ‰็ ๅ•ๆŠ—Anti-IL13-monoclonal-antibody +[23]ย 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-13 inhibitors
TargetsInterleukin-13
Therapy Area/IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)EczemaDermatitis +[14]ย 
Global Approved IndicationsDermatitis, Atopic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2023/11/16
Country/TerritoryCzechiaBelgiumBulgaria +[48]ย 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesTanox Inc
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly Japan KkEli Lilly And CompanyVetter Pharma-Fertigung Gmbh & Co Kg +[6]ย 
Inactive CompaniesTanox IncF. Hoffmann-La Roche LtdGenentech Inc +[4]ย 
Active IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)EczemaDermatitis +[9]ย 
Inactive IndicationsAlzheimer DiseaseIdiopathic Pulmonary FibrosisPulmonary Disease, Chronic Obstructive +[5]ย 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG